In the Phase 2a obesity study, GSBR-1290 demonstrated a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% 1 (p<0.0001) at 12 weeks. At Week 12, 67% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback